DexCom Inc

Dexcom released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes, highlighting gaps in continuous glucose monitoring awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. The survey of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries found that 89% of HCPs believe CGM helps assess treatment adherence between appointments, yet 55% of surveyed Type 2 patients reported limited knowledge of the technology, and reimbursement and coverage challenges were cited by 90% of U.S. HCPs and 53% of HCPs in the other seven countries surveyed. Among existing users, 94% said CGM helps them manage diabetes more independently and 91% use CGM data to guide treatment decisions. The report also flagged an emerging intersection between CGM and GLP-1 therapies, with 58% of Type 2 patients taking GLP-1 medicines using CGM alongside their medication versus only 27% of Type 2 patients not using insulin, while half of HCPs expect increasing GLP-1 use to drive CGM adoption. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team principally sponsored by Novo Nordisk, to extend its visibility within the Type 1 diabetes community and create opportunities for real-world research, education and awareness.

Tandem Diabetes Care has launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel. The small, iPhone-controlled pump uses Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes, and it offers flexible wear options and a 200-unit cartridge. The international rollout broadens Tandem's technology ecosystem for people living with diabetes outside the United States and supports the company's near-term catalyst of international expansion and ecosystem adoption. Tandem's narrative projects $1.4 billion in revenue and $63.4 million in earnings by 2029, requiring 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today, while some analysts assume revenue could reach about US$1.6 billion and earnings US$170.9 million.

DexCom reported second-quarter worldwide revenues of $1.31 billion, up 13% year over year with organic growth of 12%, as U.S. revenues rose 11% to $933 million and international revenues climbed 19% to $375 million. The company's second-quarter gross margin expanded 400 basis points to 64.1%, helped by manufacturing efficiencies and the initial G7 15 Day mix shift, and management remains on track to convert nearly 50% of its U.S. customer base to the G7 15 Day system by year-end. DexCom has submitted evidence from its nearly 300-patient CONNECT trial to CMS and expects a coverage decision by year-end, with implementation targeted for mid-2027; commercial coverage already spans the four largest PBMs, representing more than 7 million non-insulin Type 2 patients. The Zacks Consensus Estimate for 2026 earnings per share has risen 7 cents to $2.64 over the past 60 days, while the consensus for third-quarter revenues is $1.32 billion, an 9.4% improvement, and third-quarter earnings are pinned at 66 cents per share, up 8.2% year over year. Risks include tougher international comparisons in the second half, potential currency headwinds, and limited near-term revenue impact from Stelo and Nutrisense, where incremental non-CGM revenue is only in the low millions.

DexCom, Inc. announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a healthcare executive and finance leader with more than 20 years of experience in the medical technology industry, most recently serving as Vice President and Chief Financial Officer of Stryker Corporation from 2016 to 2025 and then as an advisor to Stryker's Chief Executive Officer from 2025 to 2026. President and CEO Jake Leach said the company launched a search earlier this summer for a new independent director with deep MedTech experience and a proven track record of global scale, calling Boehnlein a perfect fit as Dexcom executes against its newly announced long-range plan. Boehnlein currently serves on the boards of Inogen, Inc., where he chairs the Audit Committee, Agilent Technologies, Inc., and Sutter Health. He received bachelor's and master's degrees in professional accountancy from Mississippi State University.

DexCom's modelled fair value has been lifted modestly from US$91.64 to US$94.12 following second-quarter 2026 execution, new clinical data, and guidance updates. Several firms including Citi, Argus, Raymond James, Deutsche Bank, UBS, TD Cowen, Stifel and Mizuho raised price targets into a US$87 to US$105 range, citing strong margins, sensor rollout benefits, and potential payer coverage expansion including Medicare for Type 2 patients not on insulin. Truist and Mizuho noted a mixed setup for the broader medical technology sector, with investors still cautious on procedure volumes and capital spending. The updated model assumes revenue growth of about 11.20%, a net profit margin of about 21.85%, a future P/E multiple of about 26.4x, and a discount rate of about 7.55%.

DexCom shares have gained 34.8% in 2026, rebounding from a 14.7% decline in 2025, as investors recognize the company's improving growth profile and expanding continuous glucose monitoring opportunity. Second-quarter revenues rose 13% year over year, with U.S. revenues up 11% and international revenues jumping 19%, driven by broader reimbursement, market-share gains, and stronger patient starts. Key growth catalysts include the CONNECT trial showing a 1.6% A1c improvement in non-insulin Type 2 diabetes patients, the G7 15 Day product rollout expected to reach nearly 50% of the U.S. customer base by year-end, and international expansion including Health Canada clearance for G7 15 Day. The Zacks Consensus Estimate projects 2026 EPS of $2.64, up 26.8% year over year, and 2027 EPS of $3.08, up 16.6%, with revenues expected to grow 12.1% to $5.23 billion in 2026 and 11.6% to $5.83 billion in 2027. Competition remains intense from Abbott, MiniMed, and Senseonics, and execution risks around reimbursement and product transitions persist, but the article concludes the rally is supported by improving fundamentals rather than short-term momentum.

DexCom raised its 2026 revenue and margin outlook after reporting stronger second-quarter results. The company now expects 2026 revenues of $5.18 to $5.25 billion, up from the prior $5.16 to $5.25 billion range, implying 11 to 13 percent annual growth. DexCom also lifted its adjusted gross margin forecast to about 64 percent, adjusted operating margin guidance to 23.5 to 24 percent, and adjusted EBITDA margin guidance to 31.5 to 32 percent. Second-quarter revenues rose 13.1 percent year over year to $1.31 billion, with adjusted operating income up 48 percent to $328.3 million and adjusted operating margin expanding to 25.1 percent. The company cited manufacturing efficiencies and the initial customer switchover to its G7 15 Day sensor as key drivers, and expects to convert nearly half of its U.S. customer base to that product by year-end 2026.

Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.

DexCom's fair value estimate has been raised from $85.24 to $91.64, reflecting a moderate uplift in the price target range currently referenced for the stock. Several firms, including Raymond James, TD Cowen, Citi, Stifel, Mizuho, and Deutsche Bank, have lifted their price targets into an $88 to $96 range, citing strong second-quarter results, margin upside, and growth prospects in continuous glucose monitoring. In contrast, BofA, Canaccord, and Barclays reduced their targets in May, with Barclays maintaining an Underweight rating. The company also reported second-quarter 2026 results that supported a higher full-year outlook, received Health Canada authorization for the Dexcom G7 15 Day system, and was selected as the first participant in the FDA TEMPO Pilot Program. Additionally, DexCom announced a new share repurchase authorization of up to $1 billion through June 30, 2027.

Eight out of nine healthcare companies that reported quarterly results this week beat earnings-per-share expectations, while all nine exceeded revenue consensus. Centene posted second-quarter revenue of $53.6 billion, topping estimates by $6.1 billion, and raised its full-year revenue guidance to $193.5 billion to $197.5 billion. Boston Scientific reported revenue of $5.4 billion, beating by $70 million, but lowered its full-year net sales growth outlook to 5.5% to 6.5% year-over-year. DexCom beat on both top and bottom lines and raised the midpoint of its 2026 revenue guidance to a range of $5.18 billion to $5.25 billion. Universal Health Services was the only company to miss EPS estimates.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

DexCom reported second-quarter revenue of $1.31 billion, beating analyst estimates of $1.29 billion and growing 13.1% year on year. Adjusted earnings per share came in at $0.70, topping the consensus of $0.61 by 15.1%, while adjusted EBITDA of $421.3 million exceeded the $390.7 million forecast. The company slightly raised its full-year revenue guidance to $5.22 billion at the midpoint from $5.21 billion. Management attributed the performance to strong global demand for its continuous glucose monitoring solutions, expanded reimbursement for type 2 diabetes patients not on insulin, and rapid adoption of the G7 15-day system. DexCom also highlighted the submission of CONNECT trial data to CMS for potential Medicare coverage expansion and ongoing investments in its Ireland manufacturing facility and digital health capabilities.

The global blood glucose monitoring system market is projected to grow from USD 16.8 billion in 2025 to USD 39.4 billion by 2035, at a compound annual growth rate of 8.9%. The market is expected to reach USD 18.3 billion in 2026. Growth is driven by the introduction of AI-enabled monitoring systems, such as Roche's Accu-Chek SmartGuide continuous glucose monitoring solution launched in the Middle East in November 2025, and the rising prevalence of home healthcare. North America held the highest market share in 2025, while Asia Pacific is expected to capture a significant revenue share due to an aging population and increasing product launches. Key players include Abbott Laboratories, Medtronic, and Dexcom.

Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for people 18 years and older living with diabetes. The system is the longest-lasting and most accurate CGM authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days. It features best-in-class accuracy with an overall MARD of 8.0% and requires fewer sensor changes per month. The device is not yet available for purchase, with Dexcom Canada focusing on ensuring support and education are in place before launch.

Bell Global Equities Fund reported that DexCom's management presented robust growth targets through 2030 at its Investor Day, reassuring investors and driving a more than 25% share price increase between the event and month-end. The fund noted that despite consistently beating consensus expectations, DexCom's valuation had been subdued due to market skepticism about its long-term growth runway. The positive shift in sentiment made DexCom one of the portfolio's top monthly contributors. Bell Global Equities Fund retains its position, believing the valuation still underappreciates the penetration potential of the continuous glucose monitoring technology.

Heald announced that consumers purchasing a Dexcom Stelo or Abbott Lingo continuous glucose monitor through Heald will now receive complimentary access to its AI-powered Glucose Intelligence platform. The platform interprets glucose trends and provides AI-driven recommendations, including meal analysis, barcode scanning, wearable integration, restaurant recommendations, weekly meal and fitness plans, and community support, all within a single application. Personalized meal plans tailored to each user's glucose patterns have also been introduced. The offering is available immediately through Heald's Buy Your CGM page, with sensors typically shipping within two to three business days. Heald also offers an optional membership program that pairs Glucose Intelligence with nutritionists, fitness coaches, and behavioral coaches for those seeking additional clinical guidance.

DexCom is well positioned for growth driven by the expanding continuous glucose monitoring market and the launch of its G7 15 Day system. The company expanded commercial coverage to more than 7 million non-insulin type 2 diabetes patients and expects a Medicare reimbursement decision soon, which could unlock millions of additional users. International revenues grew 26% reported, fueled by reimbursement wins in France and Canada, while management expects nearly 50% of the installed base to migrate to the 15-day platform by year-end. Risks include uncertain CMS timing, rising input costs that could create a 50-100 basis point gross margin headwind, and a maturing U.S. market. The Zacks Consensus Estimate for 2026 earnings per share has risen 1 cent to $2.57 over the past 60 days.

Insulet has launched its Omnipod 5 Automated Insulin Delivery System in Spain. The tubeless system is indicated for people aged two years and older with type 1 diabetes and works with Abbott FreeStyle Libre 2 Plus and Dexcom G7 sensors. Spain is the 26th country where Insulet sells Omnipod products and the 20th market for Omnipod 5, part of a rapid international expansion that has seen launches in 15 countries over the past 18 months. The company also introduced Omnipod Discover, a web-based data platform for users and providers, which first launched in five Middle Eastern countries earlier this year. Spain has over 4.6 million adults with diabetes, including about 189,000 with type 1 diabetes and more than 18,500 children and adolescents requiring insulin.

StockStory identified Rocket Lab, Intuitive Surgical, and DexCom as three Nasdaq 100 stocks with promising prospects. Rocket Lab, with a market cap of $66.44 billion, achieved annual revenue growth of 55.1% over the past two years and improved its operating margin by 111.4 percentage points over five years. Intuitive Surgical, valued at $146.2 billion, posted annual revenue growth of 20.2% over the last two years and annual earnings per share growth of 21.3% over five years, supported by share repurchases. DexCom, with a market cap of $29.04 billion, recorded organic revenue growth averaging 12.5% over the past two years and expanded its free cash flow margin by 26 percentage points over five years.

DexCom announced that the FDA cleared expanded use of its Stelo Glucose Biosensor for children ages 2 and older who do not use insulin. President and CEO Jake Leach stated that glucose matters for everyone, and the company plans to broaden access to glucose biosensing while making preventive, customized care more accessible through a redesigned Stelo app. The updated app will begin rolling out in the United States in July for Apple iPhone and Android users, providing easier-to-understand glucose insights linked to food, activity, sleep, and stress. DexCom also plans to launch Stelo in the United Kingdom, Australia, New Zealand, and South Korea beginning later this year and continuing into 2027. The company noted that Type 2 diabetes and related health issues are becoming more common in young people, so children and their parents who do not use insulin can now get blood sugar tracking data without a prescription.

Abbott and DexCom are leading players in the continuous glucose monitoring market, valued at 13.4 billion dollars in 2025. Abbott's FreeStyle Libre CGM sales reached 2 billion dollars in the first quarter of 2026, up 7.5 percent year over year, though growth was affected by an international tender delay and a tough prior-year comparison. DexCom is benefiting from broader CGM access, new product launches like the G7 15 Day sensor, and expanded insurance coverage, with more than one million users connected to automated insulin delivery systems worldwide. Year to date, Abbott shares have declined 25.6 percent while DexCom shares have climbed 4.1 percent. Abbott trades at a forward price-to-sales ratio of 2.99 times, below its median of 4.63 times, while DexCom's ratio is 4.88 times, also below its median of 9.93 times. DexCom carries a Zacks Rank of 3, or Hold, while Abbott has a Zacks Rank of 4, or Sell.

DexCom announced it will begin rolling out its fully reimagined Stelo app experience in the United States starting in July, with plans to expand the platform to the United Kingdom, Australia, New Zealand and South Korea later this year and further expansion continuing into 2027. The updated app, available for Apple iPhone and Android users, aims to make glucose insights more accessible and actionable for individuals seeking to understand their metabolic health. The company also highlighted the recent FDA clearance of Stelo for pediatric use, expanding its indication to include children aged 2 years and older who are not using insulin. DexCom shares lost 0.2% following the announcement, and the stock has gained 3.8% year to date against an 18.3% decline for the industry.

Dexcom announced at Aspen Ideas: Health that its Stelo Glucose Biosensor has received FDA clearance for use in children ages 2 and older not using insulin, expanding from the previous adult-only indication. The company also detailed the July launch of a fully reimagined Stelo app for iPhone and Android in the United States, designed to make glucose insights more approachable and actionable. International expansion of Stelo is planned for the United Kingdom, Australia, New Zealand, and South Korea starting later this year and continuing into 2027. The pediatric clearance addresses rising youth-onset Type 2 diabetes, with CDC data showing a significant increase over the last 20 years and projections of up to 700% further growth.

Piper Sandler analyst Matt O'Brien raised the firm's price target on DexCom to $88 from $75 while maintaining an Overweight rating, citing greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth. The move follows the U.S. Food and Drug Administration's clearance of DexCom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children aged two and older who do not use insulin, expanding on the March 2024 clearance for adults. Earlier in the week, TD Cowen analyst Joshua Jennings also raised his price target on DexCom to $95 from $75 with a Buy rating, highlighting the company's position in the T2NIT coverage expansion initiative and the compelling CONNECT dataset for payers.

Three non-pharmaceutical companies—Teladoc Health, Ollie's Bargain Outlet, and DexCom—are positioned to benefit from the growing GLP-1 weight-loss drug market. Teladoc's telehealth platform is seeing rapid growth in obesity management and GLP-1 prescription initiation, helping it beat first-quarter 2026 revenue expectations by about $3 million at $614 million. Discount retailer Ollie's could gain from GLP-1 patients needing new wardrobes, reporting 14% year-over-year sales growth and planning 75 new store openings this year. DexCom's continuous glucose monitoring devices are increasingly paired with GLP-1 treatments, and the company has launched over-the-counter products to reach a wider population interested in metabolic health.